Abstract
Background: Early detection of renal cell carcinoma using serum/plasma biomarkers remains challenging. To validate clinical performance of potential candidate markers for kidney tumors, three-marker assay composed of nicotinamide N-methyltransferase (NNMT), L-plastin (LCP1), and nonmetastatic cells 1 protein (NM23A) was evaluated. Methods: Patients with kidney cancer and control group were included in the clinical evaluation. Participants were divided into cohorts representing the training group of control group including healthy and benign tumors (n 102) and patients with kidney cancer (n 87) that were used to identify criteria for scoring. Then, we developed a three-marker assay that was validated with a cohort of test group samples (n 100). A scoring method based on the cut-point of each of the three markers was used to evaluate the diagnostic performance of the marker combination. Results: Plasma levels of NNMT, LCP1, and NM23A were highly elevated in patients with kidney cancer (P < 0.0001). In 289 blind sample tests with control subjects (n 175) and patients with kidney cancer (n 114), the diagnostic accuracy of NNMT alone and the three-marker assay was 0.913 and 0.932, respectively. When 90% specificity was defined, the sensitivity of NNMT and the three-marker assay was 71.9% and 95.7%, respectively. The predictive value of the three-marker assay was 87.2% (+PPV) and 97% (PPV). Conclusions: The composite assay with NNMT, LCP1, and NM23A was a promising novel serum marker assay for the early detection of malignant kidney tumors covering subtypes of RCC with high diagnostic characteristics. Impact: NNMT/LCP1/NM23A triple markers could be a helpful screening assay to detect early RCC.
| Original language | English |
|---|---|
| Pages (from-to) | 390-398 |
| Number of pages | 9 |
| Journal | Cancer Epidemiology Biomarkers and Prevention |
| Volume | 22 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2013 Mar 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Epidemiology
- Oncology
Cite this
}
Composite three-marker assay for early detection of kidney cancer. / Kim, Dong Su; Choi, Young Deuk; Moon, Mihyang; Kang, Suki; Lim, Jong Baeck; Kim, Kyung Min; Park, Kyung Mok; Cho, Nam Hoon.
In: Cancer Epidemiology Biomarkers and Prevention, Vol. 22, No. 3, 01.03.2013, p. 390-398.Research output: Contribution to journal › Article
TY - JOUR
T1 - Composite three-marker assay for early detection of kidney cancer
AU - Kim, Dong Su
AU - Choi, Young Deuk
AU - Moon, Mihyang
AU - Kang, Suki
AU - Lim, Jong Baeck
AU - Kim, Kyung Min
AU - Park, Kyung Mok
AU - Cho, Nam Hoon
PY - 2013/3/1
Y1 - 2013/3/1
N2 - Background: Early detection of renal cell carcinoma using serum/plasma biomarkers remains challenging. To validate clinical performance of potential candidate markers for kidney tumors, three-marker assay composed of nicotinamide N-methyltransferase (NNMT), L-plastin (LCP1), and nonmetastatic cells 1 protein (NM23A) was evaluated. Methods: Patients with kidney cancer and control group were included in the clinical evaluation. Participants were divided into cohorts representing the training group of control group including healthy and benign tumors (n 102) and patients with kidney cancer (n 87) that were used to identify criteria for scoring. Then, we developed a three-marker assay that was validated with a cohort of test group samples (n 100). A scoring method based on the cut-point of each of the three markers was used to evaluate the diagnostic performance of the marker combination. Results: Plasma levels of NNMT, LCP1, and NM23A were highly elevated in patients with kidney cancer (P < 0.0001). In 289 blind sample tests with control subjects (n 175) and patients with kidney cancer (n 114), the diagnostic accuracy of NNMT alone and the three-marker assay was 0.913 and 0.932, respectively. When 90% specificity was defined, the sensitivity of NNMT and the three-marker assay was 71.9% and 95.7%, respectively. The predictive value of the three-marker assay was 87.2% (+PPV) and 97% (PPV). Conclusions: The composite assay with NNMT, LCP1, and NM23A was a promising novel serum marker assay for the early detection of malignant kidney tumors covering subtypes of RCC with high diagnostic characteristics. Impact: NNMT/LCP1/NM23A triple markers could be a helpful screening assay to detect early RCC.
AB - Background: Early detection of renal cell carcinoma using serum/plasma biomarkers remains challenging. To validate clinical performance of potential candidate markers for kidney tumors, three-marker assay composed of nicotinamide N-methyltransferase (NNMT), L-plastin (LCP1), and nonmetastatic cells 1 protein (NM23A) was evaluated. Methods: Patients with kidney cancer and control group were included in the clinical evaluation. Participants were divided into cohorts representing the training group of control group including healthy and benign tumors (n 102) and patients with kidney cancer (n 87) that were used to identify criteria for scoring. Then, we developed a three-marker assay that was validated with a cohort of test group samples (n 100). A scoring method based on the cut-point of each of the three markers was used to evaluate the diagnostic performance of the marker combination. Results: Plasma levels of NNMT, LCP1, and NM23A were highly elevated in patients with kidney cancer (P < 0.0001). In 289 blind sample tests with control subjects (n 175) and patients with kidney cancer (n 114), the diagnostic accuracy of NNMT alone and the three-marker assay was 0.913 and 0.932, respectively. When 90% specificity was defined, the sensitivity of NNMT and the three-marker assay was 71.9% and 95.7%, respectively. The predictive value of the three-marker assay was 87.2% (+PPV) and 97% (PPV). Conclusions: The composite assay with NNMT, LCP1, and NM23A was a promising novel serum marker assay for the early detection of malignant kidney tumors covering subtypes of RCC with high diagnostic characteristics. Impact: NNMT/LCP1/NM23A triple markers could be a helpful screening assay to detect early RCC.
UR - http://www.scopus.com/inward/record.url?scp=84876588154&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84876588154&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-12-1156
DO - 10.1158/1055-9965.EPI-12-1156
M3 - Article
C2 - 23479363
AN - SCOPUS:84876588154
VL - 22
SP - 390
EP - 398
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
SN - 1055-9965
IS - 3
ER -